ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Magnetic nanoparticle contrast agents for MRI: structure-property relationships,Nanotechnology · 2026Review
- Carbon Dots Meet MRI: Metal Doping for a Smart Contrast Agent Design.International journal of molecular sciences · 2026Review
- Targeted Nanotheransotics: Integration of Preclinical MRI and CT in the Molecular Imaging and Therapy of Advanced Diseases.Nanotheranostics · 2024Review
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Exploring atherosclerosis imaging with contrast-enhanced MRI using PEGylated ultrasmall iron oxide nanoparticles.Frontiers in bioengineering and biotechnology · 2023Article
- Current Nanomedicine for Targeted Vascular Disease Treatment: Trends and Perspectives.International journal of molecular sciences · 2022Review
- Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.Analytical chemistry · 2021Article
- High density lipoprotein mimicking nanoparticles for atherosclerosis.Nano convergence · 2020Review
- Biomedical Imaging: Principles, Technologies, Clinical Aspects, Contrast Agents, Limitations and Future Trends in Nanomedicines.Pharmaceutical research · 2019Review
- Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015Review
- In vivo multimodal magnetic particle imaging (MPI) with tailored magneto/optical contrast agents.Biomaterials · 2015Article
- Multimodality PET/MRI agents targeted to activated macrophages.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Article
- Bioabsorbable stent quo vadis: a case for nano-theranostics.Theranostics · 2014Review
- Personalized nanomedicine advancements for stem cell tracking.Advanced drug delivery reviews · 2012Review
- Molecular imaging to identify the vulnerable plaque--from basic research to clinical practice.Molecular imaging and biology · 2012Review
- Nanoformulations for molecular MRI.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Advances in nanoparticle contrast agents for molecular imaging have made magnetic resonance imaging a promising modality for noninvasive visualization and assessment of vascular and cardiac disease processes. This review provides a description of the various nanoparticles exploited for imaging cardiovascular targets. Nanoparticle probes detecting inflammation, apoptosis, extracellular matrix, and angiogenesis may provide tools for assessing the risk of progressive vascular dysfunction and heart failure. The utility of nanoparticles as multimodal probes and/or theranostic agents has also been investigated. Although clinical application of these nanoparticles is largely unexplored, the potential for enhancing disease diagnosis and treatment is considerable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.